VistaGen Therapeutics Inc. announced topline results from the PALISADE-3 Phase 3 clinical study evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not demonstrate a statistically significant improvement on the primary endpoint, as measured by the Subjective Units of Distress Scale (SUDS), with results showing no significant difference between fasedienol and placebo. No treatment difference was observed for secondary endpoints. The safety profile of fasedienol remained favorable and consistent with previous clinical trials. The results of the study have already been presented. VistaGen is reviewing the results, assessing their impact on ongoing studies, and plans to consult with the FDA while implementing cash preservation measures to extend its operational runway.